About Paragon Biosciences
Paragon Biosciences is a company based in Chicago (United States) founded in 2010 by Jeffrey S Aronin.. Paragon Biosciences has raised $311.6 million across 7 funding rounds. Paragon Biosciences offers products and services including Innovative Therapies and Regenerative Medicines.
- Headquarter Chicago, United States
- Founders Jeffrey S Aronin
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Paragon Biosciences Llc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$311.6 M (USD)
in 7 rounds
-
Latest Funding Round
$185 M (USD), Series E
Nov 09, 2022
-
Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Paragon Biosciences
Paragon Biosciences offers a comprehensive portfolio of products and services, including Innovative Therapies and Regenerative Medicines. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Innovative therapies for patients with rare neurological diseases are developed and commercialized by the company.
Regenerative medicines that restore function for severe skin and connective tissue disorders are developed.
Unlock access to complete
Unlock access to complete
Funding Insights of Paragon Biosciences
Paragon Biosciences has successfully raised a total of $311.6M across 7 strategic funding rounds. The most recent funding activity was a Series E round of $185 million completed in November 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Series E — $185.0M
-
First Round
First Round
(14 Aug 2018)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2022 | Amount | Series E - Paragon Biosciences | Valuation |
investors |
|
| Nov, 2022 | Amount | Series D - Paragon Biosciences | Valuation |
investors |
|
| Mar, 2021 | Amount | Series D - Paragon Biosciences | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Paragon Biosciences
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Paragon Biosciences
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Paragon Biosciences Comparisons
Competitors of Paragon Biosciences
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Paragon Biosciences
Frequently Asked Questions about Paragon Biosciences
When was Paragon Biosciences founded?
Paragon Biosciences was founded in 2010 and raised its 1st funding round 8 years after it was founded.
Where is Paragon Biosciences located?
Paragon Biosciences is headquartered in Chicago, United States. It is registered at Chicago, Illinois, United States.
Who is the current CEO of Paragon Biosciences?
Jeffrey S Aronin is the current CEO of Paragon Biosciences. They have also founded this company.
Is Paragon Biosciences a funded company?
Paragon Biosciences is a funded company, having raised a total of $311.6M across 7 funding rounds to date. The company's 1st funding round was a Series D of $35M, raised on Aug 14, 2018.
What does Paragon Biosciences do?
Paragon Biosciences was founded in 2010 and is headquartered in Chicago, United States. Operations focus on the healthcare sector, where advisory services are offered to companies seeking strategic guidance. The firm is led by Jeffrey S. Aronin as founder and CEO. Expertise is applied across various healthcare subsectors, supporting decision-making and growth initiatives within the industry.
What products or services does Paragon Biosciences offer?
Paragon Biosciences offers Innovative Therapies and Regenerative Medicines.